November 5, 2021 10:34 AM EDTUpdated 10:50 AM

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics

Zachary Brennan

Senior Editor

House Democrats are on the cusp of passing two major pieces of Biden’s agenda Friday, but Medicare drug price negotiations — once the centerpiece of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics

Zachary Brennan

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

Roivant brings rare disease program closer as Immunovant CEO retires

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Dem­s' $100B deal re­duced fur­ther: Medicare drug price ne­go­ti­a­tions pushed to 13 years for bi­o­log­ics

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics